HC Wainwright & Co. Maintains Buy on Kronos Bio, Lowers Price Target to $2.5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Kronos Bio (NASDAQ:KRON) but reduced the price target from $9 to $2.5.
December 19, 2023 | 11:16 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Kronos Bio's price target has been lowered from $9 to $2.5 by HC Wainwright & Co., although the Buy rating is maintained.
The reduction in price target by HC Wainwright & Co. suggests a lower valuation for Kronos Bio, which could lead to a negative short-term reaction in the stock price. However, maintaining a Buy rating indicates the analyst still sees potential upside, mitigating the negative impact to some extent.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100